Olema Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
OLMA$7.36+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(Amounts in thousands)
| Years Ended December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $ | (162,451) | $ | (129,474) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization expense | 490 | 393 | ||
| Non-cash lease expense | 1,176 | 1,150 | ||
| Non-cash interest income on marketable securities | (6,292) | (8,175) | ||
| Stock-based compensation expense, including employee stock purchase plan expense | 17,586 | 22,582 | ||
| Loss on disposal of equipment | — | 9 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | (5,418) | (429) | ||
| Other assets and long-term deposits | (6,145) | (2,957) | ||
| Accounts payable | 4,598 | 2,510 | ||
| Other current liabilities | 10,984 | 11,202 | ||
| Operating lease liabilities | (1,244) | (1,162) | ||
| Net cash used in operating activities | (146,716) | (104,351) | ||
| Cash flows from investing activities: | ||||
| Purchase of equipment | — | (159) | ||
| Maturities of marketable securities | 344,962 | 301,592 | ||
| Purchases of marketable securities | (500,722) | (394,959) | ||
| Net cash used in investing activities | (155,760) | (93,526) | ||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of shares upon follow-on public offering, net of issuance costs of $13,110 | 205,390 | — | ||
| Proceeds from issuance of shares under at-the-market offering, net of issuance costs of $166 | — | 22,787 | ||
| Proceeds from 2024 private placement, net of issuance costs of $6,498 | — | 243,501 | ||
| Payment of issuance costs for shares issued under 2024 private placement | (6,514) | — | ||
| Proceeds from borrowings under Credit Facility (Note 13) | 3,000 | — | ||
| Proceeds from exercise of stock options | 8,391 | 1,671 | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 1,030 | 859 | ||
| Net cash provided by financing activities | 211,297 | 268,818 | ||
| Net (decrease) increase in cash and cash equivalents | (91,179) | 70,941 | ||
| Cash and cash equivalents at beginning of period | 139,480 | 68,539 | ||
| Cash and cash equivalents at end of period | $ | 48,301 | $ | 139,480 |
| Supplemental disclosure of cash flow information | ||||
| Exchange common stock shares for pre-funded warrants | $ | 29,379 | $ | 31,054 |
| Right-of-use asset obtained in exchange for operating lease liabilities | $ | 896 | $ | — |
| Unpaid issuance costs related to follow-on public offering and 2024 private placement | $ | 578 | $ | 6,500 |
| Research and development project deposit applied against study invoices | $ | 177 | $ | 748 |
| System implementation cost included in other current liabilities | $ | (95) | $ | (337) |
Olema Pharmaceuticals, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.